Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild‑type disease during the early disease course

  • Authors:
    • Jung‑Min Lee
    • Dana‑Adriana Botesteanu
    • Yusuke Tomita
    • Akira Yuno
    • Min‑Jung Lee
    • Elise C. Kohn
    • Christina M. Annunziata
    • Ursula Matulonis
    • Lauren A. MacDonald
    • Jayakumar R. Nair
    • Kimberley M. Macneil
    • Jane B. Trepel
  • View Affiliations

  • Published online on: August 7, 2019     https://doi.org/10.3892/ol.2019.10731
  • Pages: 3914-3924
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunosuppressive myeloid‑derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are associated with immunologic tolerance and poor prognosis in ovarian cancer (OvCa). We hypothesized that women with germline BRCA1 and BRCA2 mutation‑associated (gBRCAm) OvCa would have fewer circulating immunosuppressive immune cells compared to those with BRCA wild‑type (BRCAwt) disease during their early disease course (<5 years post‑diagnosis) where gBRCAm is a favorable prognostic factor. We collected and viably froze peripheral blood mononuclear cells (PBMCs) from patients with recurrent OvCa olaparib clinical trials (NCT01445418/NCT01237067). Immune subset analyses were performed using flow cytometry for Tregs, exhausted CD8+ T cells, monocytes and MDSCs. Functional marker expression, including cytotoxic T lymphocyte‑associated protein 4 (CTLA‑4), T cell immunoglobulin and mucin domain 3 (TIM‑3) and programmed cell death protein 1 (PD‑1) was evaluated. Data were analyzed using FlowJo. Pretreatment PBMCs were collected from 41 patients (16 gBRCAm/25 BRCAwt). The percentage of MDSCs among viable CD45+ PBMC was lower in gBRCAm OvCa compared with BRCAwt OvCa (median 0.565 vs. 0.93%, P=0.0086) but this difference was not seen in those women >5 years post‑diagnosis. CD8+ T cells among viable CD45+ PBMCs and CTLA‑4+/CD8+ T cells were higher in gBRCAm carriers than patients with BRCAwt, in particular for those <5 years post‑diagnosis (median 20.4 vs. 9.78%, P=0.031 and median MFI 0.19 vs. 0.22, P=0.0074, respectively). TIM‑3 expression on Tregs was associated with poor progression‑free survival, independent of gBRCAm status (P<0.001). Our pilot data suggested that patients with gBRCAm OvCa may have fewer circulating MDSCs but higher CD8+ T cells in PBMCs during their early disease course. This may contribute to the observed survival benefit for these women in their first post‑diagnosis decade.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lee, J., Botesteanu, D., Tomita, Y., Yuno, A., Lee, M., Kohn, E.C. ... Trepel, J.B. (2019). Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild‑type disease during the early disease course. Oncology Letters, 18, 3914-3924. https://doi.org/10.3892/ol.2019.10731
MLA
Lee, J., Botesteanu, D., Tomita, Y., Yuno, A., Lee, M., Kohn, E. C., Annunziata, C. M., Matulonis, U., MacDonald, L. A., Nair, J. R., Macneil, K. M., Trepel, J. B."Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild‑type disease during the early disease course". Oncology Letters 18.4 (2019): 3914-3924.
Chicago
Lee, J., Botesteanu, D., Tomita, Y., Yuno, A., Lee, M., Kohn, E. C., Annunziata, C. M., Matulonis, U., MacDonald, L. A., Nair, J. R., Macneil, K. M., Trepel, J. B."Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild‑type disease during the early disease course". Oncology Letters 18, no. 4 (2019): 3914-3924. https://doi.org/10.3892/ol.2019.10731